HikalNSE:HIKAL -1.09%67 Net Margin % is 2.79% as of Mar. 2026, which is 52% below its 10-year median of 5.86. GuruFocus rates NSE:HIKAL with a GF Score™ of 67/100 and a GF Value™ of ₹275.89 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 954 Drug Manufacturers companies, Hikal ranks worse than 70.44% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Hikal's Net Income for the
three
months ended in Mar. 2026 was ₹144 Mil. Hikal's Revenue for the
three
months ended in Mar. 2026 was ₹5,170 Mil. Therefore, Hikal's net margin for the quarter that ended in Mar. 2026 was 2.79%.
The historical rank and industry rank for Hikal's Net Margin % or its related term are showing as below:
NSE:HIKAL'
s Net Margin % Range Over the Past 10 Years
Min: -2.88 Med: 5.86 Max: 8.33
Current: -2.88
NSE:HIKAL's Net Margin % is ranked worse than 70.44% of 954
companies
in the Drug Manufacturers industry
Industry Median: 5.695
vs NSE:HIKAL: -2.88
Hikal (NSE:HIKAL) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Hikal Net Margin % Related Terms
Hikal Net Margin % Historical Data
* Premium members only.
The historical data trend for Hikal's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hikal's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikal Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikal's Net Margin % distribution charts can be found below:
* The bar in red indicates where Hikal's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hikal (NSE:HIKAL) has a Net Margin % of 2.79% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Hikal and its competitors. This is 52% below median its historical median of 5.86. According to the industry distribution chart, Hikal ranks #672 out of 954 companies in the Drug Manufacturers industry, placing it in the top 70.4%.
Is Hikal's Net Margin % too high?
Hikal's current Net Margin % of 2.79% is 52% below median its 10-year median of 5.86. The Drug Manufacturers industry median Net Margin % is 5.70. Hikal's value of 2.79% is 51% below this industry median. Based on the distribution chart, Hikal ranks #672 out of 954 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Hikal has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikal's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikal ranks #672 out of 954 companies for Net Margin %. This places Hikal in the lower half of its industry. The industry median Net Margin % is 5.70. Hikal's value of 2.79% is 51% below this benchmark. While the company's 10-year median is 5.86 vs. the industry median of 5.70, Hikal has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.70, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hikal's current Net Margin % of 2.79% is 51% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Hikal and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hikal's current Net Margin % is 2.79%, which is 52% below median its own 10-year median of 5.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikal stock overvalued right now?
Based on GuruFocus' analysis, Hikal (NSE:HIKAL) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹275.89, compared to a current price of ₹218.96 — trading 20.6% below its estimated fair value. The current Net Margin % is 2.79%, which is 52% below median its 10-year median of 5.86 and 51% below the Drug Manufacturers industry median of 5.70. Hikal's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Hikal (NSE:HIKAL), the current Net Margin % is 2.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikal (NSE:HIKAL) Overvalued in 2026?
Based on GuruFocus' analysis, Hikal stock appears to be undervalued.
The current stock price of ₹218.96 is trading 20.6% below its estimated GF Value™ of ₹275.89.
GuruFocus considers Hikal to be Modestly Undervalued.
Key valuation signals for NSE:HIKAL:
Net Margin %: 2.79% (52% below median its 10-year median of 5.86)
GF Value™: ₹275.89 vs. price of ₹218.96 (20.6% below fair value)
Industry Position: 51% below the Drug Manufacturers median (#672 of 954)
No single metric tells the full story. See the NSE:HIKAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikal Ltd manufactures chemical intermediates, specialty chemicals, active pharmaceutical ingredients, and contract research activities. Its products are distributed to the pharmaceutical, biotech, agrochemical, and specialty chemical industries. Its segments include Crop Protection and Pharmaceuticals. The majority of the revenue is derived from the pharmaceutical segment.
67GF Score
Get the complete analysis for NSE:HIKAL
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:HIKAL has been successfully added to your 
